- Home
- EW
as 03-28-2025 4:00pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 42.1B | IPO Year: | 2000 |
| Target Price: | $79.95 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.97 | EPS Growth: | 202.39 |
| 52 Week Low/High: | $58.93 - $95.73 | Next Earning Date: | 04-24-2025 |
| Revenue: | $5,439,500,000 | Revenue Growth: | 8.57% |
| Revenue Growth (this year): | 10.16% | Revenue Growth (next year): | 9.73% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Mar 26 '25 | Sell | $70.87 | 11,250 | $797,267.25 | 30,387 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Feb 28 '25 | Sell | $70.95 | 11,250 | $796,326.99 | 30,387 | |
| LORANGER STEVEN R | EW | Director | Feb 14 '25 | Sell | $76.42 | 5,739 | $438,575.53 | 60,372 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Feb 13 '25 | Sell | $75.76 | 11,250 | $852,271.87 | 30,387 | |
| STONE HEISZ LESLIE | EW | Director | Feb 13 '25 | Sell | $75.86 | 5,739 | $435,370.87 | 30,035 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating
Argus Research
3 days ago
EW: Raising target price to $75.00
Medical Device Network
9 days ago
Medtronic’s Evolut trial outcome could shift US TAVR market
Morningstar Research
18 days ago
Analyst Report: Edwards Lifesciences Corporation
Insider Monkey
18 days ago
Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group
Simply Wall St.
24 days ago
Edwards Lifesciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Argus Research
24 days ago
EW: Lowering target price to $63.00
Argus Research
a month ago
EW: Lowering target price to $64.00
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.